journal
MENU ▼
Read by QxMD icon Read
search

Multiple Sclerosis and related Disorders

journal
https://www.readbyqxmd.com/read/28104262/editors-welcome
#1
EDITORIAL
Gavin Giovannoni, Chris Hawkes, Fred Lublin, Emmanuelle Waubant
No abstract text is available yet for this article.
January 2017: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/28104261/multiple-sclerosis-association-of-gelatinase-b-matrix-metalloproteinase-9-with-risk-and-clinical-course-the-disease
#2
Ana Valado, Maria João Leitão, António Martinho, Rui Pascoal, João Cerqueira, Inês Correia, Sónia Batista, Lívia Sousa, Inês Baldeiras
BACKGROUND: Multiple sclerosis (MS) is an autoimmune disease characterized by inflammation and axonal degeneration of the central nervous system and a leading cause of disability in young adults. The matrix metalloproteinases in general and specially gelatinase B/metalloproteinase-9 (MMP-9) plays a role in the pathogenesis of multiple sclerosis. OBJECTIVE: To investigate the presence of the MMP-9 -1562C/T polymorphism in a Portuguese population of MS patients and assess its impact in susceptibility and course of the disease...
January 2017: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/28104260/robot-guided-ankle-sensorimotor-rehabilitation-of-patients-with-multiple-sclerosis
#3
Yunju Lee, Kai Chen, Yupeng Ren, Jongsang Son, Bruce A Cohen, James A Sliwa, Li-Qun Zhang
BACKGROUND: People with multiple sclerosis (MS) often develop symptoms including muscle weakness, spasticity, imbalance, and sensory loss in the lower limbs, especially at the ankle, which result in impaired balance and locomotion and increased risk of falls. Rehabilitation strategies that improve ankle function may improve mobility and safety of ambulation in patients with MS. This pilot study investigated effectiveness of a robot-guided ankle passive-active movement training in reducing motor and sensory impairments and improving balance and gait functions...
January 2017: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/28104259/utility-of-extension-views-in-spondylotic-myelopathy-mimicking-transverse-myelitis
#4
Brittani L Conway, Michelle J Clarke, Timothy J Kaufmann, Eoin P Flanagan
Cervical spondylotic myelopathy is a common cause of myelopathy and may mimic transverse myelitis. We report a 55 year-old lady with subacute myelopathy initially treated with glatiramer acetate for suspected clinically isolated syndrome. MRI head and spine revealed a single short cervical cord T2-hyperintense lesion with enhancement just below a region of moderate stenosis. Cerebrospinal fluid revealed elevated oligoclonal bands. Repeat MRI 7 months later showed persistent enhancement. Dynamic MRI revealed cord compression during extension...
January 2017: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/28104258/the-impact-of-betaplus-program-on-patient-treatment-satisfaction-with-interferon-beta-1b-in-multiple-sclerosis-multicentric-cross-sectional-survey-in-the-western-balkan-countries
#5
Jelena Drulovic, Mirjana Cukic, Sanja Grgic, Evica Dincic, Ranko Raicevic, Congor Nadj, Gordana Toncev, Slobodan Vojinovic, Sarlota Mesaros, Darija Kisic Tepavcevic, Irena Dujmovic, Daliborka Tadic, Svetlana Miletic-Drakulic, Jelena Dackovic, Smiljana Kostic, Jevto Erakovic, Lorand Sakalas, Dejan Savic, Vesna Suknjaja, Vanja Martinovic, Gorica Maric, Tatjana Pekmezovic
BACKGROUND: Long-term treatment adherence to disease-modifying drugs (DMDs) may have significant impact on clinical outcomes in multiple sclerosis (MS). It has been recently emphasized that low treatment satisfaction (TS) may be an important factor for achieving high rates of treatment adherence. Interferon (IFN) beta-1b was the first DMD approved for the treatment of MS. The aims of our study were to assess TS in subjects with relapsing-remitting (RR) MS treated with IFN beta-1b in Serbia, Montenegro and the Republika Srpska, Bosnia and Herzegovina (B&H), and additionally, to evaluate the impact of patient support program on TS and adherence...
January 2017: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/28104257/no-evidence-of-disease-activity-neda-in-ms-should-include-csf-biology-towards-a-disease-free-status-score
#6
LETTER
Mickael Bonnan, Raluca Marasescu, Stéphanie Demasles, Elsa Krim, Bruno Barroso
The concept of NEDA (no evidence of disease activity) was forged to describe relapse-free patients under treatment with recent drugs, but this goal is reached by less than half of all patients and not sustained over time. However a complete remission of disease is expected to be associated with the normalization of CSF biomarkers. On pathophysiological grounds, we propose to add the criterion of no evidence of biological activity in CSF to design a future 'disease-free status score'. This composite criterion, which should concern neurodegenerative and immune activation biomarkers, would be better suited for assessing the persistence of biological processes long before CNS atrophy occurs and should help in predicting long-term remission/progression of MS...
January 2017: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/28104256/severe-structural-and-functional-visual-system-damage-leads-to-profound-loss-of-vision-related-quality-of-life-in-patients-with-neuromyelitis-optica-spectrum-disorders
#7
Felix Schmidt, Hanna Zimmermann, Janine Mikolajczak, Frederike C Oertel, Florence Pache, Maria Weinhold, Johann Schinzel, Judith Bellmann-Strobl, Klemens Ruprecht, Friedemann Paul, Alexander U Brandt
BACKGROUND: Neuromyelitis optica spectrum disorders (NMOSD) are characterized by devastating optic neuritis attacks causing more structural damage and visual impairment than in multiple sclerosis (MS). The objective of this study was to compare vision-related quality of life in NMOSD and MS patients and correlate it to structural retinal damage and visual function. METHODS: Thirty-one NMOSD and 31 matched MS patients were included. Vision-related quality of life was assessed with the 39-item National Eye Institute Visual Function Questionnaire (NEI-VFQ)...
January 2017: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/28104255/nmosd-triggered-by-yellow-fever-vaccination-an-unusual-clinical-presentation-with-segmental-painful-erythema
#8
F Schöberl, E Csanadi, O Eren, M Dieterich, T Kümpfel
Neuromyelitis Optica Spectrum Disorder (NMOSD) is an immune-mediated disease of the central nervous system with the presence of aquaporin 4-antibodies (AQP4-abs) in most cases. We describe a patient who developed NMOSD after a yellow fever vaccination. He presented to us with an unusual painful erythema Th7-9 triggered by touch in the respective skin area due to a cervical spinal cord lesion affecting the dorsolateral parts of C6/7. To our knowledge, this is the first case of NMOSD with such a clinical presentation expanding the clinical spectrum of NMOSD...
January 2017: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/28104254/processing-speed-and-distractibility-in-multiple-sclerosis-the-role-of-sleep
#9
Viral P Patel, Lisa A S Walker, Anthony Feinstein
BACKGROUND: The effects of sleep disturbances on cognitive performance under distraction in multiple sclerosis (MS) are not known. The objective of the present study was to explore the association between an index of sleep (i.e. daytime somnolence), distractibility and the hallmark cognitive deficit in people with MS (i.e. processing speed). METHODS: MS participants (n=102) were recruited from outpatient neurology clinics. All participants completed the traditional Symbol Digit Modalities Test (SDMT)...
January 2017: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/28104253/the-effect-of-fampridine-sr-on-cognitive-fatigue-in-a-randomized-double-blind-crossover-trial-in-patients-with-ms
#10
Sarah A Morrow, Heather Rosehart, Andrew M Johnson
BACKGROUND: Cognitive fatigue (CF) is a common complaint in persons with MS (PwMS). Fampridine-SR improves ambulation, fatigue and endurance, due to enhancing action potential formation by blocking potassium channels in demyelinated axons. Thus, through this same mechanism, it is hypothesized that Fampridine-SR could improve CF. OBJECTIVE: To determine if Fampridine-SR objectively improves CF in PwMS. METHODS: Sixty PwMS of any type with CF, defined as 3 or less correct responses when comparing the last third to the first third on the Paced Auditory Serial Addition Test (PASAT), were recruited from a tertiary care MS clinic in London (ON) Canada...
January 2017: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/28104252/novel-zebrafish-eae-model-a-quick-in-vivo-screen-for-multiple-sclerosis
#11
Pushkar Kulkarni, Swapna Yellanki, Raghavender Medishetti, Dharmarajan Sriram, Uday Saxena, Perumal Yogeeswari
INTRODUCTION: Pre-clinical drug discovery for multiple sclerosis (MS) is a labor intensive activity to perform in rodent models. This is owing to the long duration of disease induction and observation of treatment effects in an experimental autoimmune encephalomyelitis (EAE) model. We propose a novel adult zebrafish based model which offers a quick and simple protocol that can used to screen candidates as a step between in vitro experiments and rodent studies. The experiments conducted for this manuscript were to standardize a suitable model of EAE in adult zebrafish and validate it using known modulators...
January 2017: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/28104251/efficacy-safety-and-pharmacokinetics-of-natalizumab-in-japanese-multiple-sclerosis-patients-a-double-blind-randomized-controlled-trial-and-open-label-pharmacokinetic-study
#12
Takahiko Saida, Jun-Ichi Kira, Shuji Kishida, Takashi Yamamura, Yukiko Sudo, Kazutaka Ogiwara, J T Tibung, Nisha Lucas, Meena Subramanyam
BACKGROUND: Natalizumab, an anti-α4 integrin monoclonal antibody, has demonstrated efficacy in phase 2 and 3 studies of predominantly Caucasian patients with relapsing-remitting multiple sclerosis (RRMS). OBJECTIVE: To evaluate the efficacy, safety, pharmacokinetics (PK), and pharmacodynamics (PD) of natalizumab in Japanese RRMS patients. METHODS: This multicenter, phase 2 study included an open-label PK/PD study in 12 patients (part A) and a double-blind, placebo-controlled, randomized (computer-generated sequence) study in 94 patients (part B)...
January 2017: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/28104250/impact-of-daclizumab-versus-interferon-beta-1a-on-patient-reported-outcomes-in-relapsing-remitting-multiple-sclerosis
#13
Ying Liu, Timothy Vollmer, Eva Havrdova, Katherine Riester, Andrew Lee, Glenn Phillips, Ping Wang, Guido Sabatella
BACKGROUND: Patient-reported outcomes (PROs) provide information on treatment effects from the patient's perspective that complement outcomes on clinical measures. In DECIDE, daclizumab demonstrated superior efficacy in reducing relapses, 24-week confirmed disability progression, and brain lesions (assessed by magnetic resonance imaging [MRI]) versus intramuscular interferon beta-1a in relapsing-remitting multiple sclerosis. OBJECTIVE: To examine the impact of daclizumab versus interferon beta-1a on PROs in DECIDE...
January 2017: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/28104249/il-17-signalling-in-astrocytes-promotes-glutamate-excitotoxicity-indications-for-the-link-between-inflammatory-and-neurodegenerative-events-in-multiple-sclerosis
#14
Milos Kostic, Nikola Zivkovic, Ana Cvetanovic, Ivana Stojanovic, Miodrag Colic
OBJECTIVE: Th-17 cells have been exclusively referred to inflammatory events in multiple sclerosis (MS), while their importance in the development of glutamate excitotoxicity and the consequent neurodegeneration has been a completely unexplored concept. Accordingly, the objective of our study was to assess IL-17A effect on astrocyte ability to metabolize and release glutamate, considering that astrocytes had the central role in glutamate homeostasis. METHODS: By using primary rat astrocyte cultures, astrocyte ability to uptake glutamate was estimated by the alterations of glutamate transporters (GLAST and GLT-1) expression, whereas changes in glutamine synthetase expression were used to estimate the ability to metabolize glutamate...
January 2017: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/28104248/continuous-hemifacial-myokymia-as-the-revealing-symptom-of-demyelinating-disease-of-the-cns
#15
Frédéric London, Nawal Hadhoum, Hélène Zéphir, Patrick Vermersch, Olivier Outteryck
Facial myokymia (FM) is an uncommon involuntary movement, disorder of the musculature supplied by the facial nerve and, characterized by spontaneous undulating, vermicular movements beneath the, skin. It has rarely been described as a form of presentation of multiple, sclerosis. We describe a 31-year-old man presenting with continuous, unilateral facial myokymia as the revealing symptom of a demyelinating, disorder of central nervous system. Brain magnetic resonance imaging, showed an ipsilateral pontine T2/FLAIR hyperintensity close to the, postgenu course of facial nerve, suggestive of a segmental demyelination, of facial nerve causing facial nuclear hyperactivity and resulting in FM...
January 2017: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/28104247/severe-rebound-after-withdrawal-of-fingolimod-treatment-in-patients-with-multiple-sclerosis
#16
Tuncay Gündüz, Murat Kürtüncü, Mefkure Eraksoy
No abstract text is available yet for this article.
January 2017: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/27919509/editors-welcome
#17
EDITORIAL
Chris Hawkes, Fred Lublin, Gavin Giovannoni, Emmanuelle Waubant
No abstract text is available yet for this article.
November 2016: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/27919508/the-evaluation-of-mri-diffusion-values-of-active-demyelinating-lesions-in-multiple-sclerosis
#18
Mohammad Abdoli, Santanu Chakraborty, Heather J MacLean, Mark S Freedman
BACKGROUND: Gadolinium (Gd) enhancement of lesions is the main radiologic marker for detection of activity in Multiple Sclerosis (MS). This study compares Diffusion weighted imaging (DWI) characteristics and enhancement to determine whether DWI can be used as an alternative to Gd administration. METHODS: A retrospective study of 72 patients who had MRI with Gd and DWI. Visual assessment and comparison of the Apparent Diffusion Coefficient (ADC) values on Gd+ lesions, all lesions showing restricted diffusion, 2 Gd- lesions and 1 area of normal-appearing white matter (NAWM) in each MRI were performed...
November 2016: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/27919507/predictors-of-long-term-interferon-discontinuation-in-newly-diagnosed-relapsing-multiple-sclerosis
#19
Marcello Moccia, Raffaele Palladino, Antonio Carotenuto, Cinzia Valeria Russo, Maria Triassi, Roberta Lanzillo, Vincenzo Brescia Morra
BACKGROUND: Interferon-β has long-term safety and efficacy profiles for Relapsing Remitting Multiple Sclerosis (RRMS). However, the increasing number of available treatments requires to improve patient profiling and to perform individualized clinical decisions. Therefore, the present study investigated predictors of Interferon-β discontinuation. METHODS: The present retrospective observational cohort study included 499 newly diagnosed, drug naïve RRMS subjects receiving Interferon-β as first disease modifying treatment (DMT), during a 7...
November 2016: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/27919506/heart-rate-variability-predicts-the-magnitude-of-heart-rate-decrease-after-fingolimod-initiation
#20
Sakari Simula, Tomi P Laitinen, Tiina M Laitinen, Päivi Hartikainen, Juha Ek Hartikainen
BACKGROUND: Fingolimod is an immunomodulator with a disease modifying effect on relapsing-remitting multiple sclerosis (RRMS). A heart rate (HR) decrease shortly after fingolimod initiation, however, requires a clinical vigilance. The aim of this study was to prospectively investigate whether cardiac autonomic regulation can predict the magnitude of HR decrease after fingolimod initiation. METHODS: Twenty-five patients with RRMS underwent ambulatory 24-h electrocardiogram recording to assess HR variability 20±16 days before fingolimod initiation (baseline) and repeated at the day of fingolimod initiation to assess the magnitude of HR decrease...
November 2016: Multiple Sclerosis and related Disorders
journal
journal
43980
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"